Preparations on Track for First Half 2021 Commercial Launch of Libmeldy (OTL-200), the First Approved Product for Metachromatic Leukodystrophy (MLD) in the EU

Filing Strategy for OTL-200 Biologics License Application (BLA) in MLD in the U.S. to be Communicated by Mid-2021 Following Additional Regulatory Interactions

Marketing Authorization Application (MAA) Filing for OTL-103 in Wiskott-Aldrich Syndrome (WAS) on Track for Year End 2021 in the EU; Followed by BLA Filing in 2022 in the U.S.

New Clinical Data for OTL-203 (for MPS-I) and OTL-201 (for MPS-IIIA) Accepted for Oral Presentation at February 2021 WORLD Symposium; Preclinical Data from Research Programs in Larger Indications Expected in 2021

$192M in Cash and Investments to Support Strategic Execution into the First Half of 2022

BOSTONandLONDON, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today outlined the companys 2021 strategic priorities in advance of its attendance at the virtual 39thAnnual J.P. Morgan Healthcare Conference. These priorities support the companys plan of building a successful commercial business in HSC gene therapy and advancing its portfolio of investigational medicines for high-value, high-need indications.

In a year that challenged how we live and work, Im extremely proud of Orchards achievements in 2020, said Bobby Gaspar, M.D., Ph.D., chief executive officer, Orchard Therapeutics. Our accomplishments were a direct result of the drive and innovation that fuels our commitment to bring our potentially life-saving HSC therapies to patients, including Libmeldy, which is the first product approved for the treatment of eligible patients with early-onset MLD in the EU. With the HSC approach to gene therapy as our scientific foundation, we are focused on the capabilities that can deliver our therapies on a global commercial scale and support our ability to also treat larger indications over time. It has been a privilege to be a pioneer in changing the way medicine is practiced in these conditions, and we look forward to another year of continued execution and scientific progress.

2021 Corporate PrioritiesOrchard has outlined the following key corporate objectives and expected milestones for 2021:

In preparation for a European launch, Orchard has put in place the commercial infrastructure to support Libmeldy as well as future product launches. The company is qualifying five treatment centers in the UK, Germany, Italy, France and the Netherlands with specialized expertise in transplant and disease area knowledge. In addition, the company expects to leverage cross-border and treatment abroad reimbursement pathways in both Europe and markets such as the Middle East and Turkey. Activities are also underway to drive timely MLD patient identification and access, including disease awareness, genetic testing and newborn screening studies, which have started or are on track to initiate in five countries in 2021.

The company also provided an update concerning the impact of the COVID-19 pandemic on certain development activities. These include restrictions to laboratory access at Orchard and third-party service providers, which is impacting the timeline to develop a specific functional potency assay for OTL-103 in WAS, as requested by the FDA. As a result, the company now expects to file a BLA for OTL-103 in the U.S. in 2022. Orchard is utilizing the benefits provided under OTL-103s RMAT designation and plans to continue interacting with the FDA in 2021 to confirm the data package for the BLA filing. In addition, with several of the follow-up visits associated with the companys active clinical trials impacted by COVID-19 travel restrictions and other trial site limitations, Orchard is using alternative data collection approaches to capture the necessary data to support future regulatory filings.

Frank Thomas, president and chief operating officer continued, Starting 2021 with a clear set of strategic priorities is crucial to our ability to effectively manage the business while fueling Orchards continued growth. Our launch preparations for Libmeldy not only mark our evolution towards a fully integrated company but establish a common manufacturing, commercial and operational infrastructure to support multiple future potential products. This work is complemented by our exciting proof-of-concept and research pipeline that we look forward to advancing internally or in partnership.

Key 2020 AchievementsOrchards key 2020 achievements are highlighted below.

Cash GuidanceThe company ended 2020 with approximately $192 million of cash and investments. The company expects that its cash, cash equivalents and marketable securities as of December 31, 2020 will enable the funding of its currently anticipated operating expenses and capital expenditure requirements into the first half of 2022. This excludes the $50 million expected to be available under the companys credit facility and any non-dilutive capital received from potential future partnerships or priority review vouchers.

About Libmeldy / OTL-200

Libmeldy (autologous CD34+ cell enriched population that contains hematopoietic stem and progenitor cells (HSPC) transduced ex vivo using a lentiviral vector encoding the human arylsulfatase-A (ARSA) gene), also known as OTL-200, has been approved by the European Commission for the treatment of MLD in eligible early-onset patients characterized by biallelic mutations in the ARSA gene leading to a reduction of the ARSA enzymatic activity in children with i) late infantile or early juvenile forms, without clinical manifestations of the disease, or ii) the early juvenile form, with early clinical manifestations of the disease, who still have the ability to walk independently and before the onset of cognitive decline. Libmeldy is the first therapy approved for eligible patients with early-onset MLD.

The most common adverse reaction attributed to treatment with Libmeldy was the occurrence of anti-ARSA antibodies. In addition to the risks associated with the gene therapy, treatment with Libmeldy is preceded by other medical interventions, namely bone marrow harvest or peripheral blood mobilization and apheresis, followed by myeloablative conditioning, which carry their own risks. During the clinical studies, the safety profiles of these interventions were consistent with their known safety and tolerability.

For more information about Libmeldy, please see the Summary of Product Characteristics (SmPC) available on the EMA website.

Libmeldy is not approved outside of the European Union, UK, Iceland, Liechtenstein and Norway. OTL-200 is an investigational therapy in the US.

Libmeldy was developed in partnership with the San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget) in Milan, Italy.

About Orchard

Orchard Therapeuticsis a global gene therapy leader dedicated to transforming the lives of people affected by rare diseases through the development of innovative, potentially curative gene therapies. Ourex vivoautologous gene therapy approach harnesses the power of genetically modified blood stem cells and seeks to correct the underlying cause of disease in a single administration. In 2018, Orchard acquired GSKs rare disease gene therapy portfolio, which originated from a pioneering collaboration between GSK and theSan Raffaele Telethon Institute for Gene Therapy inMilan, Italy. Orchard now has one of the deepest and most advanced gene therapy product candidate pipelines in the industry spanning multiple therapeutic areas where the disease burden on children, families and caregivers is immense and current treatment options are limited or do not exist.

Orchard has its global headquarters inLondonandU.S.headquarters inBoston. For more information, please visitwww.orchard-tx.com, and follow us on TwitterandLinkedIn.

Availability of Other Information About Orchard

Investors and others should note that Orchard communicates with its investors and the public using the company website (www.orchard-tx.com), the investor relations website (ir.orchard-tx.com), and on social media (TwitterandLinkedIn), including but not limited to investor presentations and investor fact sheets,U.S. Securities and Exchange Commissionfilings, press releases, public conference calls and webcasts. The information that Orchard posts on these channels and websites could be deemed to be material information. As a result, Orchard encourages investors, the media, and others interested in Orchard to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Orchards investor relations website and may include additional social media channels. The contents of Orchards website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

Forward-Looking Statements

This press release contains certain forward-looking statements about Orchards strategy, future plans and prospects, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include express or implied statements relating to, among other things, Orchards business strategy and goals, including its plans and expectations for the commercialization of Libmeldy, the therapeutic potential of Libmeldy (OTL-200) and Orchards product candidates, including the product candidates referred to in this release, Orchards expectations regarding its ongoing preclinical and clinical trials, including the timing of enrollment for clinical trials and release of additional preclinical and clinical data, the likelihood that data from clinical trials will be positive and support further clinical development and regulatory approval of Orchard's product candidates, and Orchards financial condition and cash runway into the first half of 2022. These statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, many of which are beyond Orchards control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, these risks and uncertainties include, without limitation: the risk that prior results, such as signals of safety, activity or durability of effect, observed from clinical trials of Libmeldy will not continue or be repeated in our ongoing or planned clinical trials of Libmeldy, will be insufficient to support regulatory submissions or marketing approval in the US or to maintain marketing approval in the EU, or that long-term adverse safety findings may be discovered; the risk that any one or more of Orchards product candidates, including the product candidates referred to in this release, will not be approved, successfully developed or commercialized; the risk of cessation or delay of any of Orchards ongoing or planned clinical trials; the risk that Orchard may not successfully recruit or enroll a sufficient number of patients for its clinical trials; the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical studies or clinical trials will not be replicated or will not continue in ongoing or future studies or trials involving Orchards product candidates; the delay of any of Orchards regulatory submissions; the failure to obtain marketing approval from the applicable regulatory authorities for any of Orchards product candidates or the receipt of restricted marketing approvals; the inability or risk of delays in Orchards ability to commercialize its product candidates, if approved, or Libmeldy, including the risk that Orchard may not secure adequate pricing or reimbursement to support continued development or commercialization of Libmeldy; the risk that the market opportunity for Libmeldy, or any of Orchards product candidates, may be lower than estimated; and the severity of the impact of the COVID-19 pandemic on Orchards business, including on clinical development, its supply chain and commercial programs. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements.

Other risks and uncertainties faced by Orchard include those identified under the heading "Risk Factors" in Orchards quarterly report on Form 10-Q for the quarter endedSeptember 30, 2020, as filed with theU.S. Securities and Exchange Commission(SEC), as well as subsequent filings and reports filed with theSEC. The forward-looking statements contained in this press release reflect Orchards views as of the date hereof, and Orchard does not assume and specifically disclaims any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

Contacts

InvestorsRenee LeckDirector, Investor Relations+1 862-242-0764Renee.Leck@orchard-tx.com

MediaChristine HarrisonVice President, Corporate Affairs+1 202-415-0137media@orchard-tx.com

Go here to see the original:
Orchard Therapeutics Announces 2021 Corporate Priorities Supporting the Build-out of its Commercial Business in Hematopoietic Stem Cell (HSC) Gene...

Bone Marrow Stem Cells Comments Off on Orchard Therapeutics Announces 2021 Corporate Priorities Supporting the Build-out of its Commercial Business in Hematopoietic Stem Cell (HSC) Gene… | January 12th, 2021

A brave West Lothian mum was floored after doctors found her sciatica pain was actually a symptom of a deadly blood cancer which had hollowed out her bones.

Judith Green had suffered from back pain on several occasions over the last 10 years but was repeatedly told it was likely due to a trapped nerve and would resolve itself.

The 42-year-olds pain became too much in June 2019 when she woke screaming in the middle of the night before repeatedly vomiting blood over the next two days.

She took herself to St Johns Hospital in Livingston where doctors soon made the shock diagnosis of myeloma cancer which had left her kidneys functioning at only 15 per cent.

The mum-of-two was told that the condition - which normally affects men over the age of 60 - was incurable but doctors hoped to extend her life through various treatments.

She underwent a stem cell transplant with her own cells in January 2019 but was heartbroken when medics revealed the cancer had returned just seven months later.

The former waitress has vowed to keep fighting so she can meet her future grandchildren and is urging people to register as stem cell donors in a bid to save more lives.

She explained: I remember thinking but its just a sore back. I had never heard of myeloma before I got diagnosed with it.

I 100 per cent thought I was going to hospital that day because I had sciatica. With myeloma, it eats away at your bone marrow.

My ribs were sore but I brushed it off thinking it was my new bra digging in. When my back hurt, I thought it was the new car seat causing it.

But in reality, I had almost no bone marrow. It was 90 per cent cancerous cells. I just made excuse after excuse but looking back I now realise that it was all part of it.

My kidneys were only working at 15 per cent, which explained why I was so thirsty.

Doctors immediately started Judith on a course of chemotherapy and steroids before attempting to harvest some of her remaining bone marrow.

The first attempt was unsuccessful but the next managed to gather enough cells to provide at least three more transplants.

The cells were then deep frozen before being transplanted back into the mum-of-two in January this year - a move which they hoped would buy her at least 18 more months.

But a blood test in August revealed that the myeloma had returned a lot quicker than expected meaning she now has to undergo a second transplant from a mystery donor.

They then discovered Judith had sepsis and MRSA and having no immune system and blood cancer, Judith said she was the sickest she had ever been.

She continued: They were hoping I would make it 18 months post transplant but they discovered in August that the cancer had returned and it had only worked for seven months.

Thats when we found out that they wouldnt be able to use my own cells again because it wasnt worth putting me through all that again.

So now Ill be going back on chemo in January and getting a transplant from a worldwide donor. Thankfully the transplant team has already found a match for me on the system.

Judith continued: Im really lucky that theres a match out there for me. But there are so many others, who are a lot sicker than I am, that dont have theirs yet.

The reason I wanted to speak out is to raise awareness of myeloma and stem cell donation.

You really could be giving someone a second chance at life by spitting into a tube. Back in the day it was a bone marrow transplant but now its stem cells.

Its no different from giving blood. I would just ask everyone to go have a look into it and see if they want to or are able to register.

Judith, who lives with her two sons and partner Steven (46), added: I may not be able to do some of the things I did before like go to the cinema with the boys but Im still here.

And I hope to be here long enough to see my grandkids. I know Ill keep fighting after that to see them grow up then. But for now, its just taking each day as it comes.

To find out more about stem cell donation for those aged under 30 visit https://www.anthonynolan.org/.

Those over 30 can visit https://www.dkms.org.uk/en.

Continued here:
Brave West Lothian women discovers back pain is actually deadly blood cancer - Daily Record

Bone Marrow Stem Cells Comments Off on Brave West Lothian women discovers back pain is actually deadly blood cancer – Daily Record | January 12th, 2021

Global Coronavirus pandemic has impacted all industries across the globe, Autologous Stem Cell Based Therapies market being no exception. As Global economy heads towards major recession post 2009 crisis, Cognitive Market Research has published a recent study which meticulously studies impact of this crisis on Global Autologous Stem Cell Based Therapies market and suggests possible measures to curtail them. This press release is a snapshot of research study and further information can be gathered by accessing complete report.

Checkout Inquiry for Buying or Customization of Report: https://www.cognitivemarketresearch.com/autologous-stem-cell-based-therapies-market-report#download_report

The number of coronavirus cases is increasing rapidly which has not only taken a number of lives but has also affected the global economic structure. The Coronavirus Disease Pandemic (COVID-19) has affected all parts of the world. This virus has changed all the market conditions and hampers the growth of the various sectors of the global Autologous Stem Cell Based Therapies market. The report covers rapidly altering market scenario due to COVID-19 and market fluctuation during the forecast period. Cognitive Market Research has published Autologous Stem Cell Based Therapies market report accordingly.To Get Detailed Analysis Mail us @ [emailprotected] or call us on +1-312-376-8303.

The Autologous Stem Cell Based Therapies market report is an in-depth analysis of Autologous Stem Cell Based Therapies market which provides wide array of parameters, such as industry segments size & trends, inhibitors, dynamics, drivers, opportunities & challenges, environment & policy, cost overview, porters five force analysis, and key companies profiles including business overview and recent development. The research and analysis of complete report is done by our research expertise in order to provide holistic view on Autologous Stem Cell Based Therapies market.

Any query? Enquire Here For Discount (COVID-19 Impact Analysis Updated Sample): Click Here>https://www.cognitivemarketresearch.com/autologous-stem-cell-based-therapies-market-report

The Autologous Stem Cell Based Therapies Market is Classified into:Based on Product Types:Embryonic Stem Cell, Resident Cardiac Stem Cells, Umbilical Cord Blood Stem Cells

Based on End-User/Application:{application)

Compitative Analysis

some of the key players are focusing on strategies such as new product development and acquisitions & mergers to increase their market presence. Key players operating in the market are Regeneus, Mesoblast, Pluristem Therapeutics Inc, U.S. STEM CELL INC., Brainstorm Cell Therapeutics, Tigenix, Med cell Europe. The report additionally delivers detailed information of the key players (company profile, business overview, business strategy, product description, company revenue, SWOT analysis & other relevant information).

Autologous Stem Cell Based Therapies market report provides complete SWOT analysis of each and every company involved in Autologous Stem Cell Based Therapies market report. The market is further fragmented into geographical regions providing Autologous Stem Cell Based Therapies market share in various regions. It shows highest share of Autologous Stem Cell Based Therapies product in a particular region. The report has also included impact of COVID-19 on Autologous Stem Cell Based Therapies market and its further impact on market in coming years. Geographically, this report studies the top producers and consumers, focuses on product capacity, production, value, consumption, market share and growth opportunity.

Request Free Sample Copy @https://www.cognitivemarketresearch.com/autologous-stem-cell-based-therapies-market-report

The research report categorically identifies product type and end-use applications to highlight the core developments simultaneously dominant across all regional areas and their subsequent implications on the holistic growth trajectory of Autologous Stem Cell Based Therapies Market. Additionally, report involves additional segments if required by our readers. Furthermore, Autologous Stem Cell Based Therapies market report delivers competitive analysis based on major players involved in the market. It includes prominent players with business overview, their basic information, product description as well as their recent key developments and moves. We also provide company's revenue for two consecutive years along with their research and development investment and geographical presence. The company profiling of top players includes their strategy that help new entrants to take decision more efficiently.

Important Points that are covered in the Global Autologous Stem Cell Based Therapies Market: Deep analysis of the investment scenario of the global Autologous Stem Cell Based Therapies market Information related to the ongoing research and development projects and pipeline research and development projects Business overview and business strategies of key players Impact of COVID-19 pandemic on the growth of the Autologous Stem Cell Based Therapies market Growth map on technology improvement and with an impact on market analysisCustomization of the Report: This report can be customized to meet the clients requirements. Please connect with our sales team so that we can meet your requirements.

Get A Free Sample of Autologous Stem Cell Based Therapies Market Report: https://www.cognitivemarketresearch.com/autologous-stem-cell-based-therapies-market-report#download_report

Additional pointers from the global Autologous Stem Cell Based Therapies market report: The valuation and assessment of the industry chain for the global Autologous Stem Cell Based Therapies market report is performed, which is based on distribution channels and upstream raw materials & equipment suppliers. Moreover, the market research report study also offers an overview for investigating the viability of a new project with reference to specifics concerning the project schedules, project production solutions, investment budget, and project name.

Key Questions Answered by the Report

Impact of the Covid-19 on the global Autologous Stem Cell Based Therapies market growth and sizing The top players of the global Autologous Stem Cell Based Therapies market The performance of the global Autologous Stem Cell Based Therapies market in the coming years with the current status of the market. The key factors that are driving the growth of the global Autologous Stem Cell Based Therapies market The opportunities that will drive the growth of the global Autologous Stem Cell Based Therapies market in the forecast period The structure of the global Autologous Stem Cell Based Therapies marketFor better and effective understanding of Autologous Stem Cell Based Therapies market, report has been depicted by various graphs, tables, stat charts and pie charts.

For purchasing the entire report mail us @:https://www.cognitivemarketresearch.com/autologous-stem-cell-based-therapies-market-report#download_report

About Us:Cognitive Market Research is one of the finest and most efficient Market Research and Consulting firm. The company strives to provide research studies which include syndicate research, customized research, round the clock assistance service, monthly subscription services, and consulting services to our clients. We focus on making sure that based on our reports, our clients are enabled to make most vital business decisions in easiest and yet effective way. Hence, we are committed to delivering them outcomes from market intelligence studies which are based on relevant and fact-based research across the global market.Contact Us: +1-312-376-8303Email: [emailprotected]Web: https://www.cognitivemarketresearch.com/

https://murphyshockeylaw.net/

Go here to read the rest:
Coronavirus Impact Editon of Autologous Stem Cell Based Therapies Market Report Future Development, Top Manufacturers, Technological Advancement,...

Cardiac Stem Cells Comments Off on Coronavirus Impact Editon of Autologous Stem Cell Based Therapies Market Report Future Development, Top Manufacturers, Technological Advancement,… | January 12th, 2021

DUBLIN, Jan. 11, 2021 /PRNewswire/ --

The "Cardiovascular Drug Delivery - Technologies, Markets & Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.

The cardiovascular drug delivery markets are estimated for the years 2018 to 2028 on the basis of epidemiology and total markets for cardiovascular therapeutics. The estimates take into consideration the anticipated advances and availability of various technologies, particularly drug delivery devices in the future. Markets for drug-eluting stents are calculated separately. The role of drug delivery in developing cardiovascular markets is defined and unmet needs in cardiovascular drug delivery technologies are identified.

Drug delivery to the cardiovascular system is different from delivery to other systems because of the anatomy and physiology of the vascular system; it supplies blood and nutrients to all organs of the body. Drugs can be introduced into the vascular system for systemic effects or targeted to an organ via the regional blood supply. In addition to the usual formulations of drugs such as controlled release, devices are used as well. This report starts with an introduction to molecular cardiology and discusses its relationship to biotechnology and drug delivery systems.

Drug delivery to the cardiovascular system is approached at three levels: (1) routes of drug delivery; (2) formulations; and finally (3) applications to various diseases. Formulations for drug delivery to the cardiovascular system range from controlled release preparations to delivery of proteins and peptides. Cell and gene therapies, including antisense and RNA interference, are described in full chapters as they are the most innovative methods of delivery of therapeutics. Various methods of improving the systemic administration of drugs for cardiovascular disorders are described including the use of nanotechnology.

Cell-selective targeted drug delivery has emerged as one of the most significant areas of biomedical engineering research, to optimize the therapeutic efficacy of a drug by strictly localizing its pharmacological activity to a pathophysiologically relevant tissue system. These concepts have been applied to targeted drug delivery to the cardiovascular system. Devices for drug delivery to the cardiovascular system are also described.

The role of drug delivery in various cardiovascular disorders such as myocardial ischemia, hypertension, and hypercholesterolemia is discussed. Cardioprotection is also discussed. Some of the preparations and technologies are also applicable to peripheral arterial diseases. Controlled release systems are based on chronopharmacology, which deals with the effects of circadian biological rhythms on drug actions. A full chapter is devoted to drug-eluting stents as treatment for restenosis following stenting of coronary arteries.Fifteen companies are involved in drug-eluting stents.

New cell-based therapeutic strategies are being developed in response to the shortcomings of available treatments for heart disease. Potential repair by cell grafting or mobilizing endogenous cells holds particular attraction in heart disease, where the meager capacity for cardiomyocyte proliferation likely contributes to the irreversibility of heart failure. Cell therapy approaches include attempts to reinitiate cardiomyocyte proliferation in the adult, conversion of fibroblasts to contractile myocytes, conversion of bone marrow stem cells into cardiomyocytes, and transplantation of myocytes or other cells into injured myocardium.

Advances in the molecular pathophysiology of cardiovascular diseases have brought gene therapy within the realm of possibility as a novel approach to the treatment of these diseases. It is hoped that gene therapy will be less expensive and affordable because the techniques involved are simpler than those involved in cardiac bypass surgery, heart transplantation and stent implantation. Gene therapy would be a more physiologic approach to deliver vasoprotective molecules to the site of vascular lesions. Gene therapy is not only a sophisticated method of drug delivery; it may at times need drug delivery devices such as catheters for transfer of genes to various parts of the cardiovascular system.

Selected 80+ companies that either develop technologies for drug delivery to the cardiovascular system or products using these technologies are profiled and 80 collaborations between companies are tabulated. The bibliography includes 200 selected references from recent literature on this topic. The report is supplemented with 31 tables and 9 figures.

Key Topics Covered:

Executive Summary

1. Cardiovascular Diseases

2. Methods for Drug Delivery to the Cardiovascular System

3. Cell Therapy for Cardiovascular Disorders

4. Gene Therapy for Cardiovascular Disorders

5. Drug-Eluting Stents

6. Markets for Cardiovascular Drug Delivery

7. Companies involved in Cardiovascular Drug Delivery

8. References

For more information about this report visit https://www.researchandmarkets.com/r/eizl23

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and MarketsLaura Wood, Senior Managerpress@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470For U.S./CAN Toll Free Call +1-800-526-8630For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716

Link:
Global Cardiovascular Drug Delivery Technologies, Companies & Markets to 2028: Focus on Cell Therapy, Gene Therapy, Drug-Eluting Stents - WFMZ...

Cardiac Stem Cells Comments Off on Global Cardiovascular Drug Delivery Technologies, Companies & Markets to 2028: Focus on Cell Therapy, Gene Therapy, Drug-Eluting Stents – WFMZ… | January 12th, 2021

Of late, there has been an increasing awareness regarding the therapeutic potential of stem cells for management of diseases which is boosting the growth of the stem cell therapy market. The development of advanced genome based cell analysis techniques, identification of new stem cell lines, increasing investments in research and development as well as infrastructure development for the processing and banking of stem cell are encouraging the growth of the global stem cell therapy market.

Get Exclusive PDF Sample Copy Of This Report:https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1787

One of the key factors boosting the growth of this market is the limitations of traditional organ transplantation such as the risk of infection, rejection, and immunosuppression risk. Another drawback of conventional organ transplantation is that doctors have to depend on organ donors completely. All these issues can be eliminated, by the application of stem cell therapy. Another factor which is helping the growth in this market is the growing pipeline and development of drugs for emerging applications. Increased research studies aiming to widen the scope of stem cell will also fuel the growth of the market. Scientists are constantly engaged in trying to find out novel methods for creating human stem cells in response to the growing demand for stem cell production to be used for disease management.

It is estimated that the dermatology application will contribute significantly the growth of the global stem cell therapy market. This is because stem cell therapy can help decrease the after effects of general treatments for burns such as infections, scars, and adhesion. The increasing number of patients suffering from diabetes and growing cases of trauma surgery will fuel the adoption of stem cell therapy in the dermatology segment.

Global Stem Cell Therapy Market: Overview

Also called regenerative medicine, stem cell therapy encourages the reparative response of damaged, diseased, or dysfunctional tissue via the use of stem cells and their derivatives. Replacing the practice of organ transplantations, stem cell therapies have eliminated the dependence on availability of donors. Bone marrow transplant is perhaps the most commonly employed stem cell therapy.

Osteoarthritis, cerebral palsy, heart failure, multiple sclerosis and even hearing loss could be treated using stem cell therapies. Doctors have successfully performed stem cell transplants that significantly aid patients fight cancers such as leukemia and other blood-related diseases.

Buy This Report @https://www.tmrresearch.com/checkout?rep_id=1787<ype=S

Global Stem Cell Therapy Market: Key Trends

The key factors influencing the growth of the global stem cell therapy market are increasing funds in the development of new stem lines, the advent of advanced genomic procedures used in stem cell analysis, and greater emphasis on human embryonic stem cells. As the traditional organ transplantations are associated with limitations such as infection, rejection, and immunosuppression along with high reliance on organ donors, the demand for stem cell therapy is likely to soar. The growing deployment of stem cells in the treatment of wounds and damaged skin, scarring, and grafts is another prominent catalyst of the market.

On the contrary, inadequate infrastructural facilities coupled with ethical issues related to embryonic stem cells might impede the growth of the market. However, the ongoing research for the manipulation of stem cells from cord blood cells, bone marrow, and skin for the treatment of ailments including cardiovascular and diabetes will open up new doors for the advancement of the market.

Global Stem Cell Therapy Market: Market Potential

A number of new studies, research projects, and development of novel therapies have come forth in the global market for stem cell therapy. Several of these treatments are in the pipeline, while many others have received approvals by regulatory bodies.

In March 2017, Belgian biotech company TiGenix announced that its cardiac stem cell therapy, AlloCSC-01 has successfully reached its phase I/II with positive results. Subsequently, it has been approved by the U.S. FDA. If this therapy is well- received by the market, nearly 1.9 million AMI patients could be treated through this stem cell therapy.

Another significant development is the granting of a patent to Israel-based Kadimastem Ltd. for its novel stem-cell based technology to be used in the treatment of multiple sclerosis (MS) and other similar conditions of the nervous system. The companys technology used for producing supporting cells in the central nervous system, taken from human stem cells such as myelin-producing cells is also covered in the patent.

Global Stem Cell Therapy Market: Regional Outlook

The global market for stem cell therapy can be segmented into Asia Pacific, North America, Latin America, Europe, and the Middle East and Africa. North America emerged as the leading regional market, triggered by the rising incidence of chronic health conditions and government support. Europe also displays significant growth potential, as the benefits of this therapy are increasingly acknowledged.

Asia Pacific is slated for maximum growth, thanks to the massive patient pool, bulk of investments in stem cell therapy projects, and the increasing recognition of growth opportunities in countries such as China, Japan, and India by the leading market players.

Global Stem Cell Therapy Market: Competitive Analysis

Several firms are adopting strategies such as mergers and acquisitions, collaborations, and partnerships, apart from product development with a view to attain a strong foothold in the global market for stem cell therapy.

Some of the major companies operating in the global market for stem cell therapy are RTI Surgical, Inc., MEDIPOST Co., Ltd., Osiris Therapeutics, Inc., NuVasive, Inc., Pharmicell Co., Ltd., Anterogen Co., Ltd., JCR Pharmaceuticals Co., Ltd., and Holostem Terapie Avanzate S.r.l.

To know more about the table of contents, you can click @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=1787

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to busi-ness entities keen on succeeding in todays supercharged economic climate. Armed with an experi-enced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Read the original:
Stem Cell Therapy Market Latest Report with Forecast to 2025 - Jumbo News

Cardiac Stem Cells Comments Off on Stem Cell Therapy Market Latest Report with Forecast to 2025 – Jumbo News | January 12th, 2021

Bath and body rituals add to the feeling of overall wellness from day to night.

Long baths and showers are immensely underrated. The same goes for the body rituals that follow. Its strange to think that we would be willing to spend $300 for face creams yet scrimp on nourishing oils for the body. Truth is, bath and body rituals ought to be the norm instead of being an occasional indulgence. There are countless benefits that go with an invigorating shower in the morning, energizing body oils before heading out for the day, and a relaxing bath by nighttime. Apart from hygiene, the rituals that nurture and nourish our bodies are essential for overall sense of wellness. It can awaken the senses, create a feeling of balance, ease nerves and tension.

Firm, Toned and Cellulite-Free

Plant Collagen Body Mist for firmer and younger looking skin from ADONIA ORGANICS

Our bodies change in countless ways as we age. While exercise is a great way to keep our bodies in shape, skin tends to be less supple and firm as time progresses. ADONIA ORGANICS Plant Collage Body Mist is a plant based body spritz that helps to boost natural collagen all over the body. It is a potion that I love to use as a compliment to daily workouts. Formulation helps to boost the bodys ability to produce collagen, which is responsible for keeping skin smooth and firm. The non-greasy, easily absorbed spray creates a youthful skin tone and texture.

Reduce appearance of cellulite with ADONIA ORGANICS Legtone Serum

You may also want to complement your Collagen Body Mist with ADONIA ORGANICS Legtone Serum. Utilizing organic plant stem cells that reduce the appearance of cellulite, this toning serum renders visible results by 47% within nine minutes from first application. Rosemary Verbenone boosts cell renewal while Neroli helps bring back skin elasticity. It also helps improve the appearance of stretch marks and scarring. The Legtone Serum is also great to use for arms and other parts of the body where there is cellulite.

The Miracle Marula Oil Shower

Moo and Yoo Miracle Body Lotion is infused with skin hero ingredient, Marula Oil.

Many of us are in the habit of choosing a body wash and lotion based solely on scent. Oftentimes, we forget to look into ingredients or the sustainability practices that go into our bath and body products. MOO AND YOOs MIRACLE LOTION and BODY WASH leaves skin feeling squeaky clean and fresh without use of harmful fragrances. The company uses recyclable glass containers, which makes for a chic addition to the bath and body vanity shelf. Since getting into more mindful and sustainable beauty, plastics containers have become eye sores in the boudoir.

The Miracle Body Was from MOO AND YOO is packed with anti oxidants and ingredients with anti ... [+] inflammatory properties.

The Miracle Body Wash is blended with Marual Oil and Icelandic Moss, which act as an antioxidant. A soft powdery scent enhances that clean and fresh feeling after cleansing with the Miracle Body Wash. Following purification, the Miracle Body Lotion will help to revitalize skin, leaving a soft and nourished feel all day long. This duo is great to use for daily showers that set the tone for an amazing day.

Young, Fabulous and Polished at the Farmhouse

Just like facial skin, our bodies also need the regular exfoliation to scrub off dead skin cells. This allows for the skin to better absorb nutrients from hydrating creams, lotions or oils. During the winter, a scrub or body polish is recommended for addressing dry, flaky skin. FARMHOUSE FRESH Muscadine Moonshine Liquor Infused Body Polish is an intoxicatingly invigorating skin treat that helps to stimulate skin renewal. Formulated with Georgia muscadine grapes, sea salt and a small batch of Moonshine (distilled in Austin, Texas), this delicious body cocktail will leave skin feeling like silk. Its delicious scent will also leave you wanting morejust as you would your favorite happy hour cocktail.

Farmhouse Fresh's Muscadine Moonshine Liquor Infused Body Polish is an intoxicatingly delicious skin ... [+] treat that help to stimulate skin renewal

Moondip Back To Youth Ageless Mousse by FARMHOUSE FRESH is an ultra light body whip infused with ... [+] peptides and retinol to keep skin youthful.

After a body polish, pamper skin with the Moondip Back To Youth Ageless Body Mousse. This light-as-air anti-aging body whip is formulated with fresh notes of winter mint, apple, amber and greens. It glides like clouds against skin without the greasy or sticky feel. Infusion of age defying peptides and retinol visibly improve appearance of skin especially when applied over necklines, arms, legs and chest. Ageless Body Mousse is the jar to keep on your bedside for a pre slumber self care treat.

An Undisturbed Staycation

The Feelist Staycation Detoxifying Salt Soak is formulated with Broad Spectrum CBD, Himalayan, Epsom ... [+] and sea salts

CBD is a wonder ingredient for relaxation as well as alleviating pains and aches. It has also worked beautifully in soothing inflammation. THE FEELISTs best-selling Staycation Detoxifying Salt Soak is a treat that the body will particularly enjoy after an intense workout. This purifying soak is formulated with Broad Spectrum CBD, Himalayan, Epsom and sea salts to soothe and relax the senses. Light a candle, enjoy a glass (or two or three) or Pinot and soak in all the goodness on a Friday night.

The Feelist Do Not Disturb Extra Strength Body Cream will ease lull you into your deepest slumber ... [+] yet.

For a complete bath and body spa experience, top off your bath and body ritual with Do Not Disturb Extra Strength Body Cream. This restorative and relaxing cream is infused with an extra dose of Broad Spectrum CBD, essential oils and natural extracts that will ease lull you into your deepest slumber yet. This body cream is also idea for addressing inflammation and body cramps.

Magic at Midnight

Pink Moon's Midnight Melody Body and Hair Oil is hydrating, calming and multipurpose oil formulated ... [+] with essences of Night Blooming Tuberose, Petitgrain, and Ylang Ylang

Over the holidays, PINK MOON launched its very own calming body oil in small batches called Midnight Melody Body and Hair Oil. Since my very own bottle arrived, its been sitting on my bedside. This fresh, fragrance and clean formula of organic flower seed, apricot kernel and meadow foam is great for after a warm evening bath. Pat on slightly damp skin and allow to sink into skin. This will leave the surface feeling clean smooth and hydrated. You can also add a few drops into your bath for the most soothing bath after a long day of work from home. Essences of tuberose, ylang ylang, peppery wood and petit grain transport ease the senses into deep relaxation. What makes this the holy grail of oils is that you can also wear it as a hair oil or perfume. I love to massage this onto my scalp at night for hair that is soft, silky and revitalized.

Glow Like A Goddess

The newly launched Dry Body Oil from HIGH ON LOVE is infused with cannabis oil to give hair and skin ... [+] a goddesses glow without the greasy feel.

Self care rituals that leave you feeling and looking good are priceless. I particularly love pampering the body with oils and creams that help to amp confidence and sense of self. For years, oils that help create that glow from within radiance have been my go-to everything I set out to paint the town red. HIGH ON LOVEs Dry Body Oil is a gem that nourishes and illuminates skin. This non-greasy, cannabis seed oil formula softens and hydrates skin without the unwanted shine. For optimum results, apply all over the body. You may also use this for hair. Gently massage to allow the oils to soak. Tip: Use this body oil just before putting on that slip dress youve been waiting to wear for a special night out on town.

The Truth About Dry Brushing

The Perfect Skin Brush from ROSEBUD is made using sustainably sourced materials like sisal and ... [+] beechwood, resulting in the ideal skin lymphatic massager.

It was only very recently when my good friend and health guru Chechel Joson suggested I add dry brushing to my wellness routine. It exfoliates from dead skin and boosts lymphatic drainage, she explained. Skin is also visibly smoother and silkier after dry brushing. A few days following the conversation, ROSE BUDs Perfect Skin Brush arrived in the mail as on cue. Made using sustainably sourced sisal and beeechwood that paddle is firm enough to render maximum results even with light pressure. The key to dry brushing is to work towards the lymph nodes near the armpits and groin area. Start with a five-minute brushing routine and extend as the days progress. Follow your dry brushing routine with a warm (not hot0 shower) using a gentle body cleanser. Other benefits of brushing include: detoxification and better immune function. Tip: Try a quick dry brushing session just before a post-workout shower to feel completely energized in the mornings.

Soak, Disconnect and Breathe

PURSOMA's Just Breathe Ritual is a clearing sea salt concoction infused with clearing eucalyptus, ... [+] rosemary, lavender, and ginger.

Flu and allergy season has many of us looking for ways to ease and soothe discomforts from sneezing, sniffles and congestion. Peppermint and eucalyptus essential oils are great natural remedies now occupying prime real estate by the bedside. Ive also recently added a calming and clearing eucalyptus bath treatment with PURSOMAs Just Breathe Ritual to the current routine. This highly therapeutic French Grey Sea Salt concoction, infused natural essential oils gives sinuses relief and supports immune strength. After 20 minutes of undisturbed me-time immersed in this ritual, mind and body emerges energized and feeling brand new.

Here is the original post:
Bath And Body Routines That Make You Look And Feel Good From Day To Night - Forbes

Skin Stem Cells Comments Off on Bath And Body Routines That Make You Look And Feel Good From Day To Night – Forbes | January 12th, 2021

DUBLIN--(BUSINESS WIRE)--The "Organ and Tissue Transplantation and Alternatives" report has been added to ResearchAndMarkets.com's offering.

This report offers forecasts, by product segment, from 2018 through 2024, including supporting analyses for projections. Product segments covered consist of the solid organ (e.g., kidneys, liver, heart-lung, pancreas, intestines) and the tissue transplantation (e.g., bone, skin, cornea, heart valve) markets, along with the pharmaceuticals that accompany each market.

Also included are experimental xenografts and artificial organs; tissue transplants; and cell transplants (e.g., bone marrow, cord blood, peripheral blood, islet cell). The report touches on the use of fetal cells, stem cells, and altered cancer cells.

The arrangement of this report offers an overview of the key elements in the transplantation process: tissue typing, procurement and preservation, immunosuppressants for solid organ and tissue transplants, and postoperative monitoring. International markets are discussed, and information is provided on industry structure and the regulatory environment.

Within each section are discussions of commercialization opportunities for each segment of the market. New or emerging devices, techniques, and pharmaceuticals are highlighted.

Profiles of leading companies involved with solid organ transplantation, tissue transplantation, and alternative technologies are included. The report provides information on company placement within the market and strategic analyses of the companies' available and emerging products.

An appendix featuring various terms and processes used in transplantation is provided at the end of the report.

This report cites autologous products only in relation to their impact on the market for allografts. It does not include blood products, except for peripheral and umbilical cord blood as a source of stem cells.

Companies Mentioned

Report Includes:

Key Topics Covered:

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Chapter 3 Market and Technology Background

Chapter 4 Market Dynamics

Chapter 5 Market Breakdown by Product & Devices

Chapter 6 Market Breakdown by Region

Chapter 7 Impact of COVID-19

Chapter 8 Overview of Donation Process

Chapter 9 Regulations & Reimbursement

Chapter 10 Competitive Landscape

Chapter 11 Company Profiles

Chapter 12 Appendix: Acronyms

For more information about this report visit https://www.researchandmarkets.com/r/c4x7cw

See the original post:
Worldwide Organ and Tissue Transplantation and Alternatives Industry to 2024 - Featuring Mylan, Novartis & Pfizer Among Others -...

Skin Stem Cells Comments Off on Worldwide Organ and Tissue Transplantation and Alternatives Industry to 2024 – Featuring Mylan, Novartis & Pfizer Among Others -… | January 12th, 2021

This report outlines the investigative study that was conducted by a team of world renowned scientists, doctors including Hyuck Hoon KWON, Steven Hoseong YANG, Joon LEE, Byung Chul PARK, Kui Young PARK, Jae Yoon JUNG, Youin BAE,and Gyeong-Hun at Oaro Dermatology Institute (Seoul, South Korea), Guam Dermatology Institute (Guam, USA), Department of Dermatology, Dankook University, College of Medicine (Cheonan, South Korea), Department of Dermatology, Chung-Ang University, College of Medicine (Seoul, South Korea), and Department of Dermatology, Dongtan Sacred Heart Hospital, Hallym University College of Medicine (Hwaseong, South Korea). Researchers involved in this study evaluated the clinical efficacy and safety of adipose tissue stem cell-derived exosomes as an adjuvant therapy after application of fractional CO2laser for acne scars. 25 patients consisting of 18 men and 7 women, between ages 19 and 54, 12 with Fitzpatrick Skin Type 3 and 13 with Fitzpatrick skin type 4 and atrophic acne scars, underwent the 12-week prospective, double-blind, randomized, split-face trial. Each received three consecutive treatment sessions of fractional CO2laser to the whole face, with a follow-up evaluation, and a post- laser split face regimen, where one side of each patient's face was treated with an adipose tissue stem cell-derived exosome gel. Exosomes in this study were acquired from human ASC-CM by ExoSCRT technology developed by ExoCoBio Inc., and the other side of the face was treated with control gel. Findings revealed that the adipose tissue stem cell-derived exosome-treated sides of the face had achieved a significantly greater improvement than the control sides at the final follow-up visit (percentage reduction in echelle d'evaluation clinique des cicatrices d'acne scores: 32.5 vs 19.9%, p<0.01). Treatment-related erythema was milder, and post-treatment downtime was shorter on the applications of human adipose tissue stem cell-derived exosome-treated side.

The investigative study proved that a variety of applications of human adipose tissue stem cell-derived exosomes can serve as a novel cell-free therapeutic strategy in the regenerative and aesthetic medical fields and demonstrated the suitability of adipose tissue stem cell derived exosomes as an adjuvant treatment modality in combination with fractional carbon dioxide laser for the treatment of acne scars.

This reportis an open access article under the CC BY-NC license Society for Publication of Acta Dermato-Venereologica.

"The science is clearly demonstrating that exosomes are the wave of the future not just for aesthetics but for many other areas of medicine, and the richest source of this material, by far, is adipose tissue," says Dr. Randy Miller, M.D., F.A.C.S.

Facial atrophic acne scarring is a psychologically damaging condition that can cause emotional, mental, and social disability. "With a huge percentage of the world population struggling with this condition, the need for widening of therapeutic options was astoundingly clear," says Dr. Diane Duncan, M.D., F.A.C.S. who added, "While ablative fractional carbon dioxide laser resurfacing has demonstrated clinical efficacy in acne scar treatments, patients have sustained side-effects during post-procedural wound healing and had demanded improvement. The adjuvant application of adipose-derived stem cell conditioned medium with synergistic effects in augmenting treatment responses and reducing adverse effects through its potential to accelerate tissue rejuvenation is a victory for those suffering."

The sentiments have been echoed by so many other medical professionals, including, Dr. JD McCoy, NMP, whose patient roster includes professional athletes who do not have time for extended downtime and need to recover fast. "Since implementing the addition of Exosome Regenerative Complex powered by ExoSCRT into my protocol, I've observed a significant improvement in the speed of healing, skin quality and comfort during recovery," said Dr. Richard Jin, M.D., PhD. "Patients suffering from acne scarring range in all ages, and the pain that they feel is very real. Ensuring that my patients receive the best treatment results with the least amount of downtime and discomfort is non-negotiable, and that's why I choose to integrate Exosome Regenerative Complex powered by ExoSCRT, into all of my treatments."

Exosomes are lipid bilayer-enclosed extracellular vesicles, 30200 nm in diameter, produced by almost all cells and present in all body fluids (810). They are regarded as an essential mediator of intercellular communication by transferring proteins and genetic material between cells. Several studies have shown that mesenchymal stem cell-derived exosomes carry the essential properties of mesenchymal stem cells suggesting that exosomes may be a compelling alternative in regenerative and aesthetic medicine, as they would avoid most of the problems associated with live mesenchymal stem cell-based therapy. Interestingly, recent studies have shown that human adipose tissue stem cell-derived exosomes possess the critical properties of stem cells and are as potent as mesenchymal stem cells in the repair of various organ injuries.

BENEV's Exosome Regenerative Complex powered by ExoSCRT was developed and designed in tandem with the 4th largest exosome research company in the world, ExoCoBio. The intensive dual action complex is quickly absorbed into the skin, delivering the concentrated power of over 2.5 billion lyophilized exosomes, potent growth factors, peptides, co-enzymes, minerals, amino acids and vitamins. The paraben-free, steroid-free, and hypoallergenic patented technologies and ingredients are clinically proven to rejuvenate and regenerate the skin. "Lyophilizing exosomes maximize topical therapeutic potential. Making them ideal for treatments," says Dr. Richard Goldfarb, M.D., F.A.C.S.

ExoCoBio's ExoSCRT, is an innovative patented purification method of separating and refining 0.1 pure exosomes from stem cell conditioned media. The concentration of materials is significantly greater than what can be achieved with a product such as PRP. Studies have shown that this product increases fibroblast production by 180% and collagen production by 300%.

BENEV Company Inc. Medical Advisory Board Members:

Richard Jin, MD, PhD, BENEV's Chief Medical Director, studied at the Boston University School of Medicine, Harvard Medical School and the University of California Irvine. He completed research in the areas of cardiovascular disease, pulmonary hypertension, antioxidant enzyme properties, cell signaling, cellular redox mechanisms, free radical-induced oxidant stress, platelet biology, growth factors, and wound healing. For more information visitwww.rjclinicalinstitute.com

Richard M. Goldfarb, M.D, F.A.C.S., graduated from the University of Health Sciences /Finch University, The Chicago Medical School with top honors in Surgery. He completed his surgical training atNortheastern Ohio College of Medicine. He did additional training in cosmetic surgery at theUniversity of Pennsylvania, Department of Plastic Surgery andYale University. Dr. Goldfarb's 30 years of combined experience in General, Vascular, and Cosmetic Surgery provides his patients with the surgical expertise they are seeking. Dr. Goldfarb established the Center for SmartLipo & Plastic Surgery in 2007. For more information visitwww.centerforsmartlipo.com

Diane I. Duncan, M.D., F.A.C.S., obtained her medical degree from the Tulane University School of Medicine. She is certified by the American Board of Plastic Surgery and is a member of several plastic surgery professional societies, including the American Society of Plastic Surgeons (ASPS), the American Society of Aesthetic Plastic Surgeons (ASAPS) and the International Society of Aesthetic Plastic Surgeons (ISAPS). In addition to these affiliations, Dr. Duncan is a fellow of the American College of Surgeons (ACS). Dr. Duncan joined our Medical Advisory Board with over 30 years of experience in private practice as a plastic surgeon. She is an internationally recognized speaker and educator in plastic surgery and has delivered presentations at industry conferences around the world. She has also authored medical journal articles on a variety of subjects in plastic surgery and currently serves as a member of the editorial review board for theAesthetic Surgery Journal. For more information visit http://www.drdianeduncan.com

Randy B. Miller, M.D., is a board certified cosmetic and reconstructive plastic surgeon practicing in Miami, Florida. Dr. Miller earned his Bachelor of Arts in psychology and a Master's degree in clinical immunology and completed medical school at Jefferson Medical College where he graduated at the top of his class. He completed his training in general surgery and otolaryngology - head and neck surgery at Thomas Jefferson University Hospital in Philadelphia. Dr. Miller performed his plastic surgery training at Baylor College of Medicine located within the Texas Medical Center in Houston, which is the largest medical center in the world. Dr. Miller is a former president of the Miami Society of Plastic Surgeons, the Florida Society of Plastic Surgeons, and the Plastic Surgeons Patient Safety Foundation. Having served five consecutive terms on the Board of Directors of the Dade County Medical Association and as a delegate to the Florida Medical Association, Dr. Miller is a member of, and has received presidential appointments from, the American Society of Plastic Surgeons. In addition to his role as a clinical professor in the Division of Plastic Surgery at the University of Miami, Dr. Miller serves as a plastic surgery resident mentor. For many years he has served as the liaison between the University of Miami, Division of Plastic Surgery, and the Miami Society of Plastic Surgeons. Based on his research, publications and 25 years of clinical experience, Dr. Miller has become an internationally recognized expert in the fields of stem cell research and therapy, including human and veterinary tissue regeneration. Dr. Miller provides a uniquely comprehensive approach to aesthetics and age management. For more information visit http://www.millerplasticsurgery.com

Dr. J.D. McCoy, NMP, received his doctorate in Naturopathic Medicine at the Canadian College of Naturopathic Medicine. He is one of the most accomplished naturopathic physicians practicing aesthetic medicine in the country. He completed an internship in internal medicine in Hawaii, and began specialized training, certification, and externship in cosmetic medicine and light-based therapies. Dr. McCoy has devoted his specialization, passion and his entire practice to the art of less-invasive cosmetic rejuvenation, weight-management, and natural bio-identical hormone therapy since 2003. Dr. McCoy's principles in the practice of aesthetic medicine include prevention, the use of natural substances (light/energy, nutrients and other natural substances), and the use of the least invasive treatments possible. Dr. McCoy finds innovative solutions that reduce or eliminate the need for more invasive surgery- beautiful results naturally. He is recognized as an innovator and physician trainer for multiple technologies and techniques in cosmetic medicine including but most certainly not limited to a Physician Member: American Academy of Cosmetic Surgery, American Academy of Aesthetic Medicine, American Society of Aesthetic Mesotherapy, International Federation for Adipose Therapeutics and Science. For more information visitwww.contourmedical.com

BENEV Company Inc.1-949-457-2222 http://www.BENEV.com

SOURCE BENEV

http://benev.com/

Read the original:
BENEV Announces Investigative Report on Combination Treatment with Human Adipose Tissue Stem Cell- derived Exosomes and Fractional CO2 Laser for Acne...

Skin Stem Cells Comments Off on BENEV Announces Investigative Report on Combination Treatment with Human Adipose Tissue Stem Cell- derived Exosomes and Fractional CO2 Laser for Acne… | January 9th, 2021

The quest for CAR-T 2.0 is gaining an mRNA player, as Cambridge, Massachusetts-based Factor Bioscience sends a spinoff racing toward the clinic.

Factor drew the curtains on Exacis Biotherapeutics on Wednesday morning, with Sollis Therapeutics co-founder Gregory Fiore at the helm of a small immuno-oncology focused team built around Factors technology. The spinoff has the rights to 51 patents and just a bit of seed money from friends and family to get it going but Fiore says an IND submission is on the horizon.

We are 18 to 24 months from an IND submission, and weve identified our first target, which will be CD19, Fiore told Endpoints News.

The company will be unveiling a CD19-targeted CAR-T and CAR-NK, Fiore said, with ROR1 as its next target.

The CEO says Exacis approach is what differentiates it from others in the crowded cell therapy field, beginning with mRNA technology in-licensed from Factor. The process starts with induced pluripotent stem cells (iPSC), which are blood or skin cells that have been engineered back into an embryonic-like stem cell state. Theyre created with mRNA reprogramming, and then edited to avoid host immune surveillance, add a CAR and enhance the cells for potency against tumors.

That iPSC is quite a robust cell. It can handle a lot of editing and the cells are able to recover from a lot of editing and manipulation, Fiore said. And the fact that no viruses or DNA are used significantly decreases the resource requirement for manufacturing, he added later.

The idea of an off-the-shelf CAR-T or CAR-NK therapy as opposed to harvesting a patients cells, engineering them into a cancer attack vehicle and reinjecting them isnt a new one. Allogene released a positive snapshot of their off-the-shelf CAR-T program at ASCO 2020, and CRISPR Therapeutics offered a glimpse at their own CAR-T success in October although it was clouded by the death of a patient given a high dose of the treatment.

Exacis team of four including co-founder James Pan and former MaxiVAX CEO Dimitrios Goundis as CBO is shooting for a Series A in the coming months to bolster its team and pipeline. The company also says its in talks with several potential development partners.

We are working towards a Series A funding to be completed in Q1 of 2021, and well use those funds to build out our internal team and lab, as well as further the development along the lines of differentiation into T and NK, obtaining CARs, really putting together these target cell types, Fiore said.

While Fiore stayed mum about the the specific terms of Exacis licensing deal with Factor, he said that Factor has a majority ownership in exchange for the execution of the license.

The CEO, who was inspired to get into the field by his fathers battle with cancer, said Factor and Exacis incentives were aligned. Theres plenty of opportunity to improve the patient experience as well as outcomes, he said.

Read more from the original source:
Factor Bioscience spins out a new cell therapy player with eyes on the clinic within 2 years - Endpoints News

Skin Stem Cells Comments Off on Factor Bioscience spins out a new cell therapy player with eyes on the clinic within 2 years – Endpoints News | January 9th, 2021

Spinogenix has been awarded a research grant from the U.S. Department of Defense (DOD) to further test its lead compound as a potential treatment of amyotrophic lateral sclerosis (ALS), the company announced.

We are pleased that the DoD has recognized the potential of our novel drug candidate to change the course of disease progression in ALS, Stella Sarraf, PhD, founding CEO at Spinogenix, said in a press release. The grants amount and its duration were not disclosed in the release.

ALS is characterized by the progressive loss of motor neurons, or the nerve cells involved in the control of voluntary movement. Although some ALS treatments can slow nerve cell degeneration, they are not disease modifying and provide only a modest survival benefit. Spinogenix also noted in its release that not all patients tolerate these treatments well.

Spinogenixslead therapy candidate is a small, orally bioavailable, molecule designed to induce an increase in synapses the point of contact between two nerve cells that allows them to communicate. Its goal is to restore these neuronal connections and reverse patients decline in cognition and motor function, two faculties often affected in neurodegenerative diseases.

Spinogenix reports that the compounds mechanism is well understood, and believed to work across all the diseases where synapse loss occurs, regardless of the underlying disease mechanism.

With this grant from the DODs Congressionally Directed Medical Research Programs, Spinogenix aims to study the potential therapy using induced pluripotent stem cells (iPSCs) derived from both ALS patients and healthy controls.

iPSCs are stem cells generated from mature cells derived from the skin or blood that can give rise to different cell types, including nerve cells, depending on the particular chemical cues they are given. When these cells are derived directly from patients, they generate cellular models that mimic the diseases genetic and clinical diversity.

Additional experiments will also be conducted in ALS animal models.

Under the grant, Spinogenix will collaborate with researchers Rita Sattler, PhD, at the Barrow Neurological Institute, and Justin Ichida, PhD, at the Keck School of Medicine of the University of South Carolina.

Spinogenixs novel approach has the potential to demonstrate that replacing lost synapses may result in drugs that can provide a meaningful benefit for patients with ALS, said Merit Cudkowicz, MD, director of the Sean M. Healey and AMG Center for ALS at Mass General Hospital.

Diana holds a PhD in Biomedical Sciences, with specialization in genetics, from Universidade Nova de Lisboa, Portugal. Her work has been focused on enzyme function, human genetics and drug metabolism.

Total Posts: 45

Ins holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Cincias e Tecnologias and Instituto Gulbenkian de Cincia. Ins currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.

Read more here:
Spinogenix Wins Grant to Advance Testing of Potential Oral Therapy - ALS News Today

Skin Stem Cells Comments Off on Spinogenix Wins Grant to Advance Testing of Potential Oral Therapy – ALS News Today | January 9th, 2021

I'm not the biggest fan of New Year's resolutions, but I like to think that as we enter the top of January there is no better time to try something new. If you haven't thought about what that something might be maybe I can inspire you. I look at every year as an opportunity to test out new products, specifically skin care because I'm always looking for ways to maintain a clear complexion.

While this task can seem like an easy one, it can also be pricey. Lucky for us, Ulta Beauty is starting 2021 with a sale that's all about treating our skin meet the Love Your Skin Event.

The epic skin-care sale has started and runs through January 23. The best part is that Ulta Beauty is sharing all the deals for each day early and, folks, this sale is so good. Products from brands like Zitsticka, Clinique, Philosophy, and more will be up to 50 percent off on certain days of the month. To make it easy for you, we organized every deal by day. Here's what's on sale this week, plus a peek at the rest of the month. Happy shopping!

ZitSticka's Killa Kit is a one-way ticket to clear skin. The bundle includes four Killa Spot Clarifying Microdart Patches, which have niacinamide to fade darkness and salicylic acid to diminish the zit, and four Cleana Cleansing Swabs that are soaked salicylic acid that can be dabbed on a pimple to help shrink it.

For brighter skin, check out the Clinique Endless Glow Moisture Surge Set. It holds the entire collection that includes a Moisture Surge 72-Hour Auto-Replenishing Hydrator, a Moisture Surge Hydrating Supercharged Concentrate, a Moisture Surge Eye 96-Hour Hydro-Filler Concentrate, and a Moisture Surge Hydrating Lotion. All of which have hyaluronic acid to ensure your skin is never dry.

Loaded with hyaluronic acid and ceramides, the It Cosmetics Confidence in A Neck Cream Anti-Aging Moisturizer works to smooth out any fine lines. And to soothe dry lips, try Becca Cosmetics' Hydra-Light Smoothing Lip Scrub. Its formula has moisturizing mango butter and coconut oil and natural sugars to exfoliate any dryness or flakiness.

The Juice Beauty Stem Cellular Anti-Wrinkle Overnight Cream & Eye Treatment is made with primrose oil, which reduces dark circles, and vitamin C to hydrate the eye area. If you're more of a mask person, the Este Lauder Perfectly Clean Multi-Action Foam Cleanser and Purifying Mask may be for you. It's a two-in-one cleanser and mask that unclogs pores using salicylic acid. Either wash it off right away like a face wash or let it sit for three minutes like a mask to prevent and calm any acne.

See the rest here:
Ulta Beautys Love Your Skin Event Is Here | January 2021 - Allure

Skin Stem Cells Comments Off on Ulta Beautys Love Your Skin Event Is Here | January 2021 – Allure | January 9th, 2021

DBMR has added a new report titled Exosome Therapeutic Market with analysis provides the insights which bring marketplace clearly into the focus and thus help organizations make better decisions. This Exosome Therapeutic Market research report understands the current and future of the market in both developed and emerging markets. The report assists in realigning the business strategies by highlighting the business priorities. It throws light on the segment expected to dominate the industry and market. It forecast the regions expected to witness the fastest growth. This report is a collection of pragmatic information, quantitative and qualitative estimation by industry experts, the contribution from industry across the value chain. Furthermore, the report also provides the qualitative results of diverse market factors on its geographies and Segments.

Exosome therapeutic market is expected to gain market growth in the forecast period of 2019 to 2026. Data Bridge Market Research analyses that the market is growing with a CAGR of 21.9% in the forecast period of 2019 to 2026 and expected to reach USD 31,691.52 million by 2026 from USD 6,500.00 million in 2018. Increasing prevalence of lyme disease, chronic inflammation, autoimmune disease and other chronic degenerative diseases are the factors for the market growth.

Get Sample Report + All Related Graphs & Charts (with COVID 19 Analysis) @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-exosome-therapeutic-market&pm

Exosomes are used to transfer RNA, DNA, and proteins to other cells in the body by making alteration in the function of the target cells. Increasing research activities in exosome therapeutic is augmenting the market growth as demand for exosome therapeutic has increased among healthcare professionals.

Increased number of exosome therapeutics as compared to the past few years will accelerate the market growth. Companies are receiving funding for exosome therapeutic research and clinical trials. For instance, In September 2018, EXOCOBIO has raised USD 27 million in its series B funding. The company has raised USD 46 million as series a funding in April 2017. The series B funding will help the company to set up GMP-compliant exosome industrial facilities to enhance production of exosomes to commercialize in cosmetics and pharmaceutical industry.

Increasing demand for anti-aging therapies will also drive the market. Unmet medical needs such as very few therapeutic are approved by the regulatory authority for the treatment in comparison to the demand in global exosome therapeutics market will hamper the market growth market. Availability of various exosome isolation and purification techniques is further creates new opportunities for exosome therapeutics as they will help company in isolation and purification of exosomes from dendritic cells, mesenchymal stem cells, blood, milk, body fluids, saliva, and urine and from others sources. Such policies support exosome therapeutic market growth in the forecast period to 2019-2026.

This exosome therapeutic market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for anAnalyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Grab Your Report at an Impressive 30% Discount! Please click Here @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-exosome-therapeutic-market&pm

Competitive Landscape and Exosome Therapeutic Market Share Analysis

Global exosome therapeutic market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, concept cars, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companys focus related to global exosome therapeutic market.

The major players covered in the report are evox THERAPEUTICS, EXOCOBIO, Exopharm, AEGLE Therapeutics, United Therapeutics Corporation, Codiak BioSciences, Jazz Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, ReNeuron Group plc, Capricor Therapeutics, Avalon Globocare Corp., CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC., Stem Cells Group among other players domestic and global. Exosome therapeutic market share data is available for Global, North America, Europe, Asia-Pacific, and Latin America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many joint ventures and developments are also initiated by the companies worldwide which are also accelerating the global exosome therapeutic market.

For instance,

Partnership, joint ventures and other strategies enhances the company market share with increased coverage and presence. It also provides the benefit for organisation to improve their offering for exosome therapeutics through expanded model range.

Global Exosome Therapeutic Market Scope and Market Size

Global exosome therapeutic market is segmented of the basis of type, source, therapy, transporting capacity, application, route of administration and end user. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Based on type, the market is segmented into natural exosomes and hybrid exosomes. Natural exosomes are dominating in the market because natural exosomes are used in various biological and pathological processes as well as natural exosomes has many advantages such as good biocompatibility and reduced clearance rate compare than hybrid exosomes.

Exosome is an extracellular vesicle which is released from cells, particularly from stem cells. Exosome functions as vehicle for particular proteins and genetic information and other cells. Exosome plays a vital role in the rejuvenation and communication of all the cells in our body while not themselves being cells at all. Research has projected that communication between cells is significant in maintenance of healthy cellular terrain. Chronic disease, age, genetic disorders and environmental factors can affect stem cells communication with other cells and can lead to distribution in the healing process. The growth of the global exosome therapeutic market reflects global and country-wide increase in prevalence of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases, along with increasing demand for anti-aging therapies. Additionally major factors expected to contribute in growth of the global exosome therapeutic market in future are emerging therapeutic value of exosome, availability of various exosome isolation and purification techniques, technological advancements in exosome and rising healthcare infrastructure.

Rising demand of exosome therapeutic across the globe as exosome therapeutic is expected to be one of the most prominent therapies for autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases treatment, according to clinical researches exosomes help to processes regulation within the body during treatment of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases. This factor has increased the research activities in exosome therapeutic development around the world for exosome therapeutic. Hence, this factor is leading the clinician and researches to shift towards exosome therapeutic. In the current scenario the exosome therapeutic are highly used in treatment of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases and as anti-aging therapy as it Exosomes has proliferation of fibroblast cells which is significant in maintenance of skin elasticity and strength.

For More Insights Get FREE Detailed TOC @https://www.databridgemarketresearch.com/toc/?dbmr=global-exosome-therapeutic-market&pm

Exosome therapeutic Market Country Level Analysis

The global exosome therapeutic market is analysed and market size information is provided by country by type, source, therapy, transporting capacity, application, route of administration and end user as referenced above.

The countries covered in the exosome therapeutic market report are U.S. and Mexico in North America, Turkey in Europe, South Korea, Australia, Hong Kong in the Asia-Pacific, Argentina, Colombia, Peru, Chile, Ecuador, Venezuela, Panama, Dominican Republic, El Salvador, Paraguay, Costa Rica, Puerto Rico, Nicaragua, Uruguay as part of Latin America.

Country Level Analysis, By Type

North America dominates the exosome therapeutic market as the U.S. is leader in exosome therapeutic manufacturing as well as research activities required for exosome therapeutics. At present time Stem Cells Group holding shares around 60.00%. In addition global exosomes therapeutics manufacturers like EXOCOBIO, evox THERAPEUTICS and others are intensifying their efforts in China. The Europe region is expected to grow with the highest growth rate in the forecast period of 2019 to 2026 because of increasing research activities in exosome therapeutic by population.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Huge Investment by Automakers for Exosome Therapeutics and New Technology Penetration

Global exosome therapeutic market also provides you with detailed market analysis for every country growth in pharma industry with exosome therapeutic sales, impact of technological development in exosome therapeutic and changes in regulatory scenarios with their support for the exosome therapeutic market. The data is available for historic period 2010 to 2017.

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email @ Corporatesales@databridgemarketresearch.com

Go here to read the rest:
Exosome Therapeutic Market Overview By Size, Share, Trends, Growth Factors and Leading Players With Detailed Analysis of Industry Structure - KSU |...

Skin Stem Cells Comments Off on Exosome Therapeutic Market Overview By Size, Share, Trends, Growth Factors and Leading Players With Detailed Analysis of Industry Structure – KSU |… | January 9th, 2021

Dublin, Jan. 06, 2021 (GLOBE NEWSWIRE) -- The "Organ and Tissue Transplantation and Alternatives" report has been added to ResearchAndMarkets.com's offering.

This report offers forecasts, by product segment, from 2018 through 2024, including supporting analyses for projections. Product segments covered consist of the solid organ (e.g., kidneys, liver, heart-lung, pancreas, intestines) and the tissue transplantation (e.g., bone, skin, cornea, heart valve) markets, along with the pharmaceuticals that accompany each market.

Also included are experimental xenografts and artificial organs; tissue transplants; and cell transplants (e.g., bone marrow, cord blood, peripheral blood, islet cell). The report touches on the use of fetal cells, stem cells, and altered cancer cells.

The arrangement of this report offers an overview of the key elements in the transplantation process: tissue typing, procurement and preservation, immunosuppressants for solid organ and tissue transplants, and postoperative monitoring. International markets are discussed, and information is provided on industry structure and the regulatory environment.

Within each section are discussions of commercialization opportunities for each segment of the market. New or emerging devices, techniques, and pharmaceuticals are highlighted.

Profiles of leading companies involved with solid organ transplantation, tissue transplantation, and alternative technologies are included. The report provides information on company placement within the market and strategic analyses of the companies' available and emerging products.

An appendix featuring various terms and processes used in transplantation is provided at the end of the report.

This report cites autologous products only in relation to their impact on the market for allografts. It does not include blood products, except for peripheral and umbilical cord blood as a source of stem cells.

By geography, the market has been segmented into North America, Europe, Asia-Pacific, and Rest of the World regions. Detailed analysis of the market in major countries such as the U.S., Germany, the U.K., Italy, France, Spain, Japan, China, India, Brazil, Mexico, GCC countries, and South Africa will be covered in the regional segment. For market estimates, data will be provided for 2019 as the base year, with estimates for 2020 and forecast value for 2024.

Story continues

Report Includes:

26 data tables and 37 additional tables

An overview of the global organ and tissue transplantation and alternatives market

Estimation of the market size and analyses of market trends, with data from 2018 to 2019, estimates for 2020, and projection of CAGR through 2024

Details about organ and tissue transplantation and alternatives, their pathophysiology and effects, and major advancement and latest trends

A look at the regulatory scenarios and initiatives by a government organization

Analysis of current and future market dynamics and identification of key drivers, restraints, and opportunities such as increasing incidence of organ donations, improved awareness about organ donations, side effects of organ and tissue transplantation, and antibiotic resistance infections

Coverage of emerging procedures and products in development and discussion on the prevalence of major chronic diseases which initiates organ damage or donation

Discussion on the role of the organ procurement organization and information on transplantation process and preparation and coverage of issues like black market donors

Impact analysis of COVID-19 on organ and tissue transplantation and alternatives market

Market share analysis of the key companies of the industry and coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies

Company profiles of major players of the industry, including Abiomed Inc., Bayer AG, F. Hoffmann-La Roche & Co., Johnson & Johnson, Novartis AG, Pfizer Inc., and XVIVO Perfusion

Growth of the global market is attributed to factors such as the growing prevalence of obesity, diabetes, cancer, and other chronic diseases which leads to organ damage, a strong product regulatory scenario, and strong investment in research and development activities by key market players including Abbott Laboratories, Cryolife Inc., Bristol-Myers Squibb, Novartis Ag, F. Hoffmann-La Roche Ltd., Medtronic, Arthrex Inc., Depuy Synthes (Johnson & Johnson), and Allosource.

Although various factors facilitate the global market for organ and tissue transplantation and alternatives, certain parameters such as challenges in HLA sequencing and gaps in supply and demand can constrain market growth. For instance, although there is an increasing need for organ transplants, the shortage of organs worldwide limits the number of transplant procedures performed, and in turn, creates an impact on transplant diagnostics procedures. An increasing number of candidates on the waiting list for organ transplant procedures worldwide further widens this gap of availability and requirement of organs for transplant purposes.

Successful organ and tissue transplantation began to arrive in the mid-1970s when tissue typing coupled with the use of cyclosporine provided more successful graft and patient survival. Today, patient and graft survival for kidney transplants is higher than 90% for the first year post-transplant, and often the success rate is 80% to 90% for five years post-transplant, with some recipients living more than 20 years after their transplant.

Continuing developments in organ procurement, organ preservation, tissue typing, and immunosuppressant use have bolstered successful transplantation surgical techniques. Evolving posttransplant drug and testing regimens have added to the success rate with close post-transplant monitoring and immunosuppressant dosage review.

Key Topics Covered:

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Chapter 3 Market and Technology Background

Organ and Tissue Transplantation and Alternatives

Cost of Care

Solid Organ Preservation

Immunosuppression

Organ Transplantation Alternatives

Trends in Organ and Tissue Transplantation Techniques and Their Alternatives

3D Tissue Assembly

Nanotechnology for Tissue Regeneration

Innovation by Small Firms

Chapter 4 Market Dynamics

Market Drivers

Increasing Epidemiology of Different Diseases Influencing Organ Transplantations

Rise in the Geriatric Population

Rising Awareness of Importance of Organ and Tissue Donation

New Therapeutic Pathways for Organ Transplantation and Their Alternatives

Market Restraints

Challenges in Human Leukocyte Antigen (HLA) Sequencing

Demand and Supply Gap

Market Opportunities

Growing Economic Benefits of Organ and Tissue Transplants

Improvement in Healthcare Infrastructure

Chapter 5 Market Breakdown by Product & Devices

Global Market for Organ and Tissue Transplantation and Alternatives

Alternative Technologies

Market Size and Forecast

Alternatives to Heart Transplantation

Surgical

Mechanical

Total Artificial Heart

Ventricular Assist Devices (VADs)

Generations of Designs

Orthopedic Alternatives

Tissue Products

Market Size and Forecast

Immunosuppressants

Market Size and Forecast

Solid Organ Preservation Solutions

Market Size and Forecast

Preservation Solutions in Development

Tissue Typing

Market Size and Forecast

Chapter 6 Market Breakdown by Region

Global Market for Organ and Tissue Transplantation and Alternatives by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Spain

Rest of Europe

Asia-Pacific

Japan

China

India

Australia and New Zealand

Rest of Asia-Pacific

Rest of the World

Market Analysis

Brazil

South Africa

Rest of the World Countries

Chapter 7 Impact of COVID-19

Introduction

Impact on Kidney Transplant Program

Impact on Pharmaceutical Companies

Donor Testing

Read this article:
Global Organ and Tissue Transplantation and Alternatives Market to 2024 - Impact Analysis of COVID-19 - Yahoo Finance

Skin Stem Cells Comments Off on Global Organ and Tissue Transplantation and Alternatives Market to 2024 – Impact Analysis of COVID-19 – Yahoo Finance | January 9th, 2021

Ah, pregnancy. That wild, magical time when youre growing new life and all that, but also experiencing crazy symptoms of bodily change daily. Today, a fire-breathing dragon might be sending shooting flames of heartburn up your oesophagus, while tomorrow, pigmentation-induced maps of lost lands might appear overnight on your body. Its a game of Russian roulette because you never know what youre going to get.

A womans skin and hair are two of the areas that undergo massive change, and just like with other pregnancy side effects, you cant predict which ones youll get. Women whove never suffered a zit in their life can suddenly sprout a crop of hormonal acne, or find their bright, taut complexion is now droopy and sallow, while others are plagued by melasma and other pigmentation issues. These problems may be cosmetic, but they can be as unsettling and debilitating for women as other medical side effects, at a time when their bodies and minds are going through profound changes.

Dr Lara Devgan, a celebrity plastic surgeon in New York, shares the most common skin and hair concerns she sees in pregnant women and shares her top tips to safely alleviate them, using a combination of products and in-clinic procedures. Devgan also has six children of her own and is no stranger to post-baby skin and hair issues herself, so this advice is definitely doctor-vetted.

Hyperpigmentation and melasma are the most common skin complaints during and after pregnancy. An even skin tone is a marker of beauty, so hyperpigmentation can be quite unsettling. Melasma is so life-altering that it is sometimes referred to as the mask of pregnancy. Hyperpigmentation is multifactorialdue to genetics, hormonal fluctuations, environmental exposures like sun and heat, stress, trauma, and other unknown phenomena. The best way to address hyperpigmentation is multifactorial as well: topical skincare products like Vitamin C and E are safe to use during pregnancy and breastfeeding. After that, Devgan suggests adding a retinol or bakuchiol serum and considering microinfusion, micro-needling, peels, and lasers for more aggressive treatment of hyperpigmentation.

Pregnancy can often be associated with dullness, dryness, and loss of skin elasticity and lustre. Devgan recommends a hyaluronic serum for increased skin hydration during pregnancy. Postpartum, she suggests laser resurfacing; Its an amazing technique for rejuvenation of the skin, offering a complete skin reset to improve lustre, texture, discolouration and fine lines. She recommends the Erbium laser for a thorough resurfacing of the skins surface; it also has a much lower risk of post-laser hyperpigmentation in Indian skin tones.

Getting wrinkles and pimples at the same time can seem like the worst of both worlds for pregnant and nursing women. The best way to address acne during pregnancy is spot treatment with benzoyl peroxide and salicylic acid-based treatments. It is also important to think about daily routines and habits like cleansing the face, regularly changing pillowcases, and sterilising cell phone screens, says Devgan. Once nursing is complete, in-office treatments can also help. Intense Pulsed Light (IPL) can be used to selectively target the bacteria that causes acne. Prescription oral medications may also help. Often, when hormones normalise after delivery, the skin also tends more toward its baseline homeostasis, says Devgan.

Hair loss is one of the most distressing things to happen in the postpartum period. Because of a rapid decrease in progesterone as well as fluctuations in oestrogen levels, the thick, beautiful hair of pregnancy begins to shed shortly after delivery. Hair loss is a complex and multifactorial issue, with many solutions, says Devgan. A supplement rich in biotin, folate, and vitamin B derivatives can help boost growth by restoring the deficient cellular building blocks needed for hair growth. Topical sprays and foams such as minoxidil (Rogaine) can also help the survivalof hair follicles. Devgan also frequently performs Platelet Rich Plasma (PRP) injections into the scalp to help boost growth factors and stem cells needed for hair growth.

8 skincare rules you need to keep in mind during your pregnancy

All the skincare and wellness changes you need to make during pregnancy

Anushka Sharma on her experience of pregnancy: You are more connected to your body, to all that is happening

More here:
A celebrity dermat's tips for new moms on how to deal with postpartum hair and skin issues - VOGUE India

Skin Stem Cells Comments Off on A celebrity dermat’s tips for new moms on how to deal with postpartum hair and skin issues – VOGUE India | January 9th, 2021

There's no better time than a national lockdown to test out the coolest new skincare/makeup/hair trends and snazzy innovations in beauty tech from the comfort of your own home. That said, there's nothing more frustrating than spending upwards of 100 on a snazzy new hair treatment or at-home facial system, only to find out it doesn't *actually* work.

Enter GLAMOUR Tries: the weekly Instagram series which sees GLAMOUR editors do all of the time-consuming (and expensive) work for you.

We've been busy trying out all of the (sometimes) wacky but always wonderful beauty crazes to take the internet by storm - from the hair pods seen backstage at Victoria Beckham during fashion week to Sarah Chapman's 138 Meso-Melt Infusion at-home facial and Ciate's nail stickers which promise an Instagram-ready manicure in minutes. These are the products that every veteran beauty sleuth is talking about - but that you want to do a bit of research into before buying.

Thanks to GLAMOUR Tries, you won't need to waste your hard-earned pennies on testing these innovations yourself. We're getting in their first, giving you the lowdown and making sure you invest in products that genuinely work. Like what you see? You can shop all of the products seen on GLAMOUR tries, with the click of a button, down below. Don't say we don't treat you.

This week, our Social Media Assistant Luca Wetherby-Matthews tried FOREO's UFO 2 LED Power Mask. Described as "the future of your weekly masking ritual", it's designed to supercharge your pampering sessions by offering you a range of treatments in one device to tackle your main skin concerns.

Condensing a 20-minute session into 90 seconds, it works in combination with the specially invented UFO-activated masks and each treatment incorporates a carefully chosen combination of temperature and pulsation intensity for maximum effect and soothing facial massage. It switches between thermotherapy (warm) to soften the skin to cryotherapy (cold) to lift and firm. That's the "Power Mask" part.

The light therapy part? The effects of the aforementioned treatments are boosted with a choice of eight light settings from antibacterial blue light to sunburn-soothing yellow LED. Of course, LED face masks are big news right now, thanks to their ability to reduce breakouts, pigmentation, rosacea symptoms, psoriasis and other side-effects of inflammation. If you don't suffer from the above complaints, LED light therapy can simply help to improve the appearance of your skin. It's a great time to invest.

Buy It Now: Cult Beauty Buy It Now: Foreo Buy It Now: John Lewis Buy It Now: LookFantastic

So, how did Luca get on? "It might seem a bit overwhelming, but something really impressive is that you can connect this to your FOREO app, and the app will guide you through your treatment based on the mask you use with it," Luca said. "It'll choose your LED settings and every other setting, doing all the hard work for you."

"My skin feels so good, and it was actually much more of a relaxing experience than I thought it was going to be. Just because it's such a quick treatment, I didn't know what to expect. But things like the cryotherapy just felt insane! So refreshing, really professional and the pulsations really relaxed my muscles. I love that you can just follow along on the app, which is so intuitive."

Buy It Now: Cult Beauty Buy It Now: Foreo Buy It Now: John Lewis Buy It Now: LookFantastic

Let us know your thoughts and check out our full review over on Instagram @glamouruk now.

Original post:
FOREO UFO 2 Review: Is It Worth The Hype? - GLAMOUR UK

Skin Stem Cells Comments Off on FOREO UFO 2 Review: Is It Worth The Hype? – GLAMOUR UK | January 9th, 2021

With a new management team spearheading Hemostemix Inc. (TSXV: HEM | OTC: HMTXF), the Company started 2021 with its critical clinical study data in hand. Raising over $4 million in 2020 and then in December adding an additional $4 million to the coffers ($2.75 million at a 50% premium), Hemostemix completed a 1-for-20 share consolidation as it charges into the New Year.

Receiving a copy of its entire clinical trial database relating to the clinical trial for Critical Limb Ischaemia (CLI) using its ACP-01 therapy (Angiogenic Cell Precursors) in November 2020 was a key event for Hemostemixs management team and it garnered real interest from the market.

Hemostemix Platform for Stem Cell Therapies

Based in Calgary and founded in 2006, Hemostemix is a clinical-stage biotechnology company specializing in blood-derived stem cell therapeutics with its lead product (ACP-01) in Stage 2 clinical trials for the treatment of CLI.

CLI is a disease caused by the narrowing of arteries in the limbs, particularly the legs, hands, and feet, causing chronic pain and soreness. Untreated CLI can sometimes require the amputation of the specific limb.

Stem cell treatments have been used for over 30 years to treat people with cancer conditions such as leukemia and lymphoma.

There are two main types of stem cell transplants: allogeneic and autologous. In an allogeneic stem cell transplant procedure, the patient receives stem cells from a donor. In an autologous stem cell transplant procedure, the patient provides themselves the stem cells for the procedure from various sources, including bone marrow or blood.

Hemostemixs autologous stem cell therapy platform uses the patients own blood to harvest the stem cells and the treatment helps to restore circulation in the damaged tissues.

Hemostemix has a strong intellectual property (IP) portfolio of 91 patents and has treated more than 500 patients with clinical results showing an improvement in 83% of the patients receiving its ACP-01 stem cell therapy.

Advantages with Hemostemixs process include the use of blood, which is safer and less invasive than extracting bone marrow, and since you are using the patients own blood, there is no immune rejection.

The clinical trials have shown that ACP-01 is safe and effective in the treatment of CLI. Now that Hemostemix has received the entire clinical trial database, it has entered into a contract with a new Clinical Research Organization (CRO) to complete the midpoint statistical analyses of the efficacy of ACP-01 and expects to publish the results this quarter.

Hemostemix Not a 1-Trick Pony Company

ACP-01 has the potential to treat other conditions such as Angina, Ischemic & Dilated Cardiomyopathy, and Peripheral Artery Disease (PAD). Currently, Hemostemix is preparing for Phase 2 trials for the treatment of Angina and is seeking joint-venture partners to fund the other Phase 2 trials.

Hemostemix has also developed NCP-01 (Neural Cellular Precursor) from blood with the potential, through building new neuronal lineage cells in a patient, to treat Alzheimers disease, Amyotrophic Lateral Sclerosis (ALS), Parkinsons disease, spinal cord injuries, and stroke-related issues. NCP-01 is currently in the R&D phase and is pre-clinical.

Market Size

According to the American Heart Association, Cardiovascular disease (CVD) accounted for approximately 1 of every 3 deaths in the United States in 2019.

Factors that increase the risk of CLI include diabetes, high cholesterol levels, high blood pressure, obesity, or smoking, all risk factors also associated with CVD.

Unfortunately, most of these factors are increasing at an alarming rate a study by the Centers for Disease Control and Prevention (CDC) in the United States, showed the prevalence of diagnosed diabetes has more than doubled from 3.3% in 1995 to 7.40% in 2015, affecting 23.4 million Americans.

According to a market research report released in 2019, the value of just the global CLI treatment market is projected to reach US$5.39 billion by 2025, up from US$3.13 billion in 2018, at an annual growth rate of 8%.

Competitive Landscape and Market Cap Comparisons

Even with Hemostemixs recent market surge, its market cap is only C$32.5 million. Similar-sized biotech companies focusing on CLI trade much higher.

Cynata Therapeutics Limited (ASX: CYP) is an Australian biotechnology company with a Phase 2 clinical-stage trial for its stem cell therapy for CLI using bone marrow and has a market cap of C$93.6 million.

Pluristem Therapeutics Inc. (NASDAQ: PSTI) is a Phase 3 bio-therapeutics company, based in Israel, that also has an allogeneic cell therapy for the treatment of CLI using the placenta and has a market cap of C$231.9 million.

In November 2020, Bristol-Myers Squibb Company (NYSE: BMY) bought MyoKardia, Inc. for US$13.1 billion. MyoKardia was a clinical-stage biopharmaceutical company that developed therapies for the treatment of cardiovascular diseases and its lead product was a Phase III clinical trial drug used in the treatment of hypertrophic cardiomyopathy (HCM).

As a company shifts from Phase 2 to Phase 3 clinical trials, the market cap often has a step-function shift higher, making it an ideal time to look at Hemostemix.

SOURCE:

Visit link:
Hemostemix steps into the new year with capital and its critical clinical study data in hand - InvestorIntel

Spinal Cord Stem Cells Comments Off on Hemostemix steps into the new year with capital and its critical clinical study data in hand – InvestorIntel | January 9th, 2021

The growth ofglioblastoma tumors can be linked to the healing process that follows a brain injury, the researchers in Canada said. They believe that mutations derailed the new cells generated during the healing process in brain injuries, such as trauma and infection or stroke, that were supposed to replace the lost cells.

The researchers said that their data suggest that right mutations in particular brain cells could be modified by injury, which would create tumors. Dr. Peter Dirks, Head of the Division of Neurosurgery and a Senior Scientist in the Developmental and Stem Cell Biology program at SickKids, said that glioblastoma could be thought of as a wound that never heals.

They think that by studying the origins of glioblastoma, they can know how cancer originates and grows as it opens up new ideas about cancer treatment. Thestudywas headed by Dirks, molecular genetics professor Dr. Gary Bader, and senior scientist Dr. Trevor Pugh.

(Photo: Wikimedia Commons)Glioblastoma multiforme - MRT T1 axial mit Kontrastmittel. Histologie bioptisch gesichert.

According to Mayo Clinic, glioblastoma is an aggressive type of cancer that can either be found in the brain or the spinal cord that forms cells called astrocytes that support nerve cells. Although it can occur at any age, glioblastoma more common in older adults.

Unfortunately, options for treating glioblastoma are still limited, and patients have an average lifespan of 15 months after diagnosis. The researchers said that it is mostly because of the extensive heterogeneity observed within tumors as they harbor diverse cells, such as the glioblastoma stem cells.

Dirk's team believes that glioblastoma stem cells are responsible for tumor growth and recurrence after treatment. After a series of tests, they confirmed that each tumor contains multiple subpopulations of cancer stem cells, making its recurrence more likely that existing therapies cannot wipe away.

Moreover, they found that glioblastoma stem cells were comingled with the cancer stem cells within the tumors, which indicates that glioblastoma is starting to form when the healing process begins as new cells replace the lost cells due to injury. Dirks said that once the mutant cell becomes involved in the healing process, it can no longer stop multiplying, spurs tumor growth.

ALSO READ: Mobile Phones Caused Brain Tumour: Italian Court Rules

Further in their study, the researchers also classified two distinct molecular states that the tumors exhibited, Genetic Engineering & Biotechnology Newsreported. These are the "Developmental" and "Injury Response" states.

The Developmental state represents a hallmark of the glioblastoma stem cells, which is similar to the rapidly dividing stem cells in the growing brain of an infant after birth. On the other hand, the Injury Response state showed an increase in the number of immune pathways and inflammation makers that indicate a healing process.

Moreover, additional experiments established that the two states are at risk of various types of gene knockouts, which means that there are many therapeutic targets linked to inflammation that had not been previously linked to glioblastoma cells' growth.

The researchers found that the two states were patient-specific, which could lean toward the Developmental state of Injury Response state. Researchers are looking into these biases to make tailored therapies that are effective on different points of the two states.

READ MORE: Brain Tumor Vaccine: Combination Therapy Offers Promising Survival Results For Glioblastoma Brain Cancer Patients

Check out more news and information on Brain Tumoron Science Times.

View original post here:
Glioblastoma Tumors Triggered by the Healing Process of Brain Injury - Science Times

Spinal Cord Stem Cells Comments Off on Glioblastoma Tumors Triggered by the Healing Process of Brain Injury – Science Times | January 9th, 2021

Stem Cell Assay Market: Snapshot

Stem cell assay refers to the procedure of measuring the potency of antineoplastic drugs, on the basis of their capability of retarding the growth of human tumor cells. The assay consists of qualitative or quantitative analysis or testing of affected tissues andtumors, wherein their toxicity, impurity, and other aspects are studied.

Get Exclusive PDF Sample Copy Of This Report:https://www.tmrresearch.com/sample/sample?flag=B&rep_id=40

With the growing number of successfulstem cell therapytreatment cases, the global market for stem cell assays will gain substantial momentum. A number of research and development projects are lending a hand to the growth of the market. For instance, the University of Washingtons Institute for Stem Cell and Regenerative Medicine (ISCRM) has attempted to manipulate stem cells to heal eye, kidney, and heart injuries. A number of diseases such as Alzheimers, spinal cord injury, Parkinsons, diabetes, stroke, retinal disease, cancer, rheumatoid arthritis, and neurological diseases can be successfully treated via stem cell therapy. Therefore, stem cell assays will exhibit growing demand.

Another key development in the stem cell assay market is the development of innovative stem cell therapies. In April 2017, for instance, the first participant in an innovative clinical trial at the University of Wisconsin School of Medicine and Public Health was successfully treated with stem cell therapy. CardiAMP, the investigational therapy, has been designed to direct a large dose of the patients own bone-marrow cells to the point of cardiac injury, stimulating the natural healing response of the body.

Newer areas of application in medicine are being explored constantly. Consequently, stem cell assays are likely to play a key role in the formulation of treatments of a number of diseases.

Global Stem Cell Assay Market: Overview

The increasing investment in research and development of novel therapeutics owing to the rising incidence of chronic diseases has led to immense growth in the global stem cell assay market. In the next couple of years, the market is expected to spawn into a multi-billion dollar industry as healthcare sector and governments around the world increase their research spending.

The report analyzes the prevalent opportunities for the markets growth and those that companies should capitalize in the near future to strengthen their position in the market. It presents insights into the growth drivers and lists down the major restraints. Additionally, the report gauges the effect of Porters five forces on the overall stem cell assay market.

Buy This Report @https://www.tmrresearch.com/checkout?rep_id=40<ype=S

Global Stem Cell Assay Market: Key Market Segments

For the purpose of the study, the report segments the global stem cell assay market based on various parameters. For instance, in terms of assay type, the market can be segmented into isolation and purification, viability, cell identification, differentiation, proliferation, apoptosis, and function. By kit, the market can be bifurcated into human embryonic stem cell kits and adult stem cell kits. Based on instruments, flow cytometer, cell imaging systems, automated cell counter, and micro electrode arrays could be the key market segments.

In terms of application, the market can be segmented into drug discovery and development, clinical research, and regenerative medicine and therapy. The growth witnessed across the aforementioned application segments will be influenced by the increasing incidence of chronic ailments which will translate into the rising demand for regenerative medicines. Finally, based on end users, research institutes and industry research constitute the key market segments.

The report includes a detailed assessment of the various factors influencing the markets expansion across its key segments. The ones holding the most lucrative prospects are analyzed, and the factors restraining its trajectory across key segments are also discussed at length.

Global Stem Cell Assay Market: Regional Analysis

Regionally, the market is expected to witness heightened demand in the developed countries across Europe and North America. The increasing incidence of chronic ailments and the subsequently expanding patient population are the chief drivers of the stem cell assay market in North America. Besides this, the market is also expected to witness lucrative opportunities in Asia Pacific and Rest of the World.

Global Stem Cell Assay Market: Vendor Landscape

A major inclusion in the report is the detailed assessment of the markets vendor landscape. For the purpose of the study the report therefore profiles some of the leading players having influence on the overall market dynamics. It also conducts SWOT analysis to study the strengths and weaknesses of the companies profiled and identify threats and opportunities that these enterprises are forecast to witness over the course of the reports forecast period.

Some of the most prominent enterprises operating in the global stem cell assay market are Bio-Rad Laboratories, Inc (U.S.), Thermo Fisher Scientific Inc. (U.S.), GE Healthcare (U.K.), Hemogenix Inc. (U.S.), Promega Corporation (U.S.), Bio-Techne Corporation (U.S.), Merck KGaA (Germany), STEMCELL Technologies Inc. (CA), Cell Biolabs, Inc. (U.S.), and Cellular Dynamics International, Inc. (U.S.).

To know more about the table of contents, you can click @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=40

About Us:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Excerpt from:
Stem Cell Assay Market Competitive Landscape Analysis with Forecast by 2025 - SoccerNurds

Spinal Cord Stem Cells Comments Off on Stem Cell Assay Market Competitive Landscape Analysis with Forecast by 2025 – SoccerNurds | January 9th, 2021

It is known that mother cells are used as treatments for cancer, Parkinsons, spinal cord injury, type 1 diabetes, or Alzheimers diseases, among other. How could it be otherwise, nowadays also It has been revealed that these types of umbilical cord bodies could help people in the disease against COVID-19.

This information has been notified by the doctor Camilo Ricordi, director of Diabetes Research Institute (DRI) and from Cell Transplant Center at the University of Miami Miller School of Medicine, and his team of international collaborators (The Cure Alliance ), who have carried out an innovative test that has shown that Umbilical Cord Derived Mesenchymal Stem Cell (UC-MSC) Infusions Safely Reduce Risk of Death and Accelerate Recovery Time for the Most Severely Covid-19 Patients, as published in the magazine Stem Cells Translational Medicine (SCTM).

The study was cleared by the United States Food and Drug Administration (FDA) in April and started by The Cure Alliance, a organization non-profit, directed by Ricordi, of which research scientists are part who share knowledge with each other that serves to accelerate the cures of all kinds of diseases.

At the beginning of the pandemic, Ricordi created the Mini-Manhattan project, which has finally yielded important results on the possible treatment of stem cells from the umbilical cord to treat the disease of COVID-19 in people who have suffered serious consequences.

To conduct the study, the researchers analyzed the cases of 24 patients hospitalized at the University of Miami Tower and Jackson Memorial Hospital that they had developed severe acute respiratory distress because of coronavirus. As part of the trial, the scientists they tried giving two infusions of mesenchymal stem cells and placebos to hospitalized patients several days apart.

Its like the technology of a smart pump in the lungs to restore the normal immune response and reverse life-threatening complications, Ricordi notes in the study.

Our results confirm the powerful anti-inflammatory and immunomodulatory effect of UC-MSCs. These cells have clearly inhibited the cytokine storm, a hallmark of severe COVID-19. Add Giacomo Lanzoni, lead author of the research.

The results are critically important not only for COVID-19, but also for other diseases characterized by aberrant and hyper-inflammatory immune responses, such as autoimmune type 1 diabetes. We are eager to apply these cells in clinical trials to halt the progression of type 1 diabetes, he concludes. Lanzoni in Stem Cells Translational Medicine (SCTM)..

Follow this link:
COVID-19 : Coronavirus I The hopeful treatment against COVID-19 with stem cells from the umbilical cord - Explica

Spinal Cord Stem Cells Comments Off on COVID-19 : Coronavirus I The hopeful treatment against COVID-19 with stem cells from the umbilical cord – Explica | January 9th, 2021

Stem cells are biological cells which have the ability to distinguish into specialized cells, which are capable of cell division through mitosis. Amniotic fluid stem cells are a collective mixture of stem cells obtained from amniotic tissues and fluid. Amniotic fluid is clear, slightly yellowish liquid which surrounds the fetus during pregnancy and is discarded as medical waste during caesarean section deliveries. Amniotic fluid is a source of valuable biological material which includes stem cells which can be potentially used in cell therapy and regenerative therapies. Amniotic fluid stem cells can be developed into a different type of tissues such as cartilage, skin, cardiac nerves, bone, and muscles. Amniotic fluid stem cells are able to find the damaged joint caused by rheumatoid arthritis and differentiate tissues which are damaged. Medical conditions where no drug is able to lessen the symptoms and begin the healing process are the major target for amniotic fluid stem cell therapy. Amniotic fluid stem cells therapy is a solution to those patients who do not want to undergo surgery. Amniotic fluid has a high concentration of stem cells, cytokines, proteins and other important components. Amniotic fluid stem cell therapy is safe and effective treatment which contain growth factor helps to stimulate tissue growth, naturally reduce inflammation. Amniotic fluid also contains hyaluronic acid which acts as a lubricant and promotes cartilage growth.

Get Free Sample Copy With Impact Analysis Of COVID-19 Of Market Report @https://www.persistencemarketresearch.com/samples/23101

With increasing technological advancement in the healthcare, amniotic fluid stem cell therapy has more advantage over the other therapy. Amniotic fluid stem cell therapy eliminates the chances of surgery and organs are regenerated, without causing any damage. These are some of the factors driving the growth of amniotic fluid stem cell therapy market over the forecast period. Increasing prevalence of chronic diseases which can be treated with the amniotic fluid stem cell therapy propel the market growth for amniotic fluid stem cell therapy, globally. Increasing funding by the government in research and development of stem cell therapy may drive the amniotic fluid stem cell therapy market growth. But, high procedure cost, difficulties in collecting the amniotic fluid and lack of reimbursement policies hinder the growth of amniotic fluid stem cell therapy market.

The global amniotic fluid stem cell therapy market is segmented on basis of treatment, application, end user and geography:

You Can Buy This PMR Healthcare Report From Here @https://www.persistencemarketresearch.com/checkout/23101

Rapid technological advancement in healthcare, and favorable results of the amniotic fluid stem cells therapy will increase the market for amniotic fluid stem cell therapy over the forecast period. Increasing public-private investment for stem cells in managing disease and improving healthcare infrastructure are expected to propel the growth of the amniotic fluid stem cell therapy market.

However, on the basis of geography, global Amniotic Fluid Stem Cell Therapy Market is segmented into six key regionsviz. North America, Latin America, Europe, Asia Pacific Excluding China, China and Middle East & Africa. North America captured the largest shares in global Amniotic Fluid Stem Cell Therapy Market and is projected to continue over the forecast period owing to technological advancement in the healthcare and growing awareness among the population towards the new research and development in the stem cell therapy. Europe is expected to account for the second largest revenue share in the amniotic fluid stem cell therapy market. The Asia Pacific is anticipated to have rapid growth in near future owing to increasing healthcare set up and improving healthcare expenditure. Latin America and the Middle East and Africa account for slow growth in the market of amniotic fluid stem cell therapy due to lack of medical facilities and technical knowledge.

Some of the key players operating in global amniotic fluid stem cell therapy market are Stem Shot, Provia Laboratories LLC, Thermo Fisher Scientific Inc. Mesoblast Ltd., Roslin Cells, Regeneus Ltd. etc. among others.

Explore Extensive Coverage of PMR`sLife Sciences & Transformational HealthLandscape

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics andmarket research methodologyto help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Naved BegPersistence Market ResearchAddress 305 Broadway, 7th Floor New York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales[emailprotected]Websitehttps://www.persistencemarketresearch.com

https://lionlowdown.com/

See original here:
The Amniotic Fluid Stem Cell Therapy Market to be synonymous to vertical growth between 2018 and 2026 - LionLowdown

Skin Stem Cells Comments Off on The Amniotic Fluid Stem Cell Therapy Market to be synonymous to vertical growth between 2018 and 2026 – LionLowdown | January 5th, 2021